US 12,312,391 B2
Anti-mutated KRAS T cell receptors
Qiong J. Wang, Highland Park, NJ (US); Zhiya Yu, Potomac, MD (US); and James C. Yang, Bethesda, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Nov. 24, 2021, as Appl. No. 17/535,318.
Application 17/535,318 is a continuation of application No. 15/528,813, granted, now 11,207,394, previously published as PCT/US2015/062269, filed on Nov. 24, 2015.
Claims priority of provisional application 62/171,321, filed on Jun. 5, 2015.
Claims priority of provisional application 62/084,654, filed on Nov. 26, 2014.
Prior Publication US 2022/0088164 A1, Mar. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/725 (2006.01); A61K 39/00 (2006.01); C07K 14/82 (2006.01); G01N 33/574 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/7051 (2013.01) [A61K 39/001164 (2018.08); A61K 39/461 (2023.05); A61K 39/4632 (2023.05); A61K 39/464464 (2023.05); C07K 14/82 (2013.01); C12Y 306/00 (2013.01); G01N 33/5748 (2013.01); A61K 38/00 (2013.01); A61K 2239/38 (2023.05); A61K 2239/54 (2023.05); G01N 2333/914 (2013.01)] 18 Claims
 
1. An isolated or purified T cell receptor (TCR) having antigenic specificity for a mutated epitope, the amino acid sequence of the mutated epitope consisting of the amino acid sequence of VVVGADGVGK (SEQ ID NO: 2),
wherein the TCR has antigenic specificity for the mutated epitope presented in the context of an HLA-A11 molecule, and wherein the TCR comprises:
(a) an α chain complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 3, an α chain CDR2 comprising the amino acid sequence of SEQ ID NO: 4, an α chain CDR3 comprising the amino acid sequence of SEQ ID NO: 5, a β chain CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a β chain CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and a β chain CDR3 comprising the amino acid sequence of SEQ ID NO: 8; and
(b) an α chain constant region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 13 and a β chain constant region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 14.